Global/National Policy Guidelines
01
NDCPA and six departments issue circular to promote children’s polio vaccine catch-up vaccination
The National Disease Control and Prevention Administration (NDCPA) and six other departments jointly issued the “Notice on Carrying Out the Work of Replacement Vaccination of the Second Dose of Inactivated Polio Vaccine for the Target Population”. Children born between March 1, 2016, and September 30, 2019, who have received only one dose of the inactivated polio vaccine are required to obtain the second dose of the inactivated polio vaccine by June 30 this year to strengthen the effect of immune protection against poliovirus type II.
https://www.ndcpa.gov.cn/jbkzzx/c100014/common/content/content_1752127835601817600.html
02
The first anniversary of free varicella vaccination in Jiangsu Province
The seventh meeting of the Standing Committee of the 14th National People’s Congress of Jiangsu Province commented on implementing the provincial government’s 2023 annual livelihood projects.
Throughout 2023, Jiangsu Province completed 114.40% of the annual task by giving 3,189,000 doses of the varicella vaccine to school-age children for free, which resulted in the province’s incidence rate of varicella among children aged 0–6 years falling by 91.1% and 73.9% respectively when compared to 2019 and 2022. The meeting concluded that future work will focus on monitoring, reporting, and disposing of abnormal reactions to vaccinations and maintaining a high immunization rate.
https://mp.weixin.qq.com/s/e37O9I6CBBmA6DVuvEYN2w
Journal Content Recommendation
03
Impact of innovative immunization strategy on PCV13 vaccination coverage among children under 5 years in Weifang city, China: A retrospective study
The pneumococcal vaccine (PCV13) free vaccination policy in Weifang attempts to incorporate PCV13 into the Chinese immunization program for the first time. In a paper published in Vaccine by Feng Luzhao of the School of Population Medicine and Public Health , Chinese Academy of Medical Sciences/Peking Union Medical College, and Wang Chunping of the School of Public Health, Shandong Second Medical University, the study found that the policy significantly increased the local PCV13 vaccination rate for children under 5 years of age, with the greatest increase in the rate of children over 12 months of age. After the implementation of the policy, parents became more inclined to have their children vaccinated with the domestically-made vaccine than with the imported vaccine.
https://doi.org/10.1016/j.vaccine.2024.01.030
04
Systematic review of cost projections of new vaccine introduction
Current guidance on cost projections for new vaccine introductions has limitations in sampling, data collection, and analytical methods. According to the review published in Vaccine, the majority of cost projections for new vaccines are conducted in middle and high-income countries. These cost projections are part of cost-effectiveness or cost-benefit analyses, which are used to help inform decision-making on the introduction of new vaccines. However, “over half of the studies utilized secondary cost data,” which creates challenges for the accuracy of cost projections for vaccine introduction. Nearly half of the studies “underestimated delivery costs of introducing new vaccines” since these did not include introduction and operational costs.
https://doi.org/10.1016/j.vaccine.2024.01.024
05
Issues with infectious disease vaccine introduction into routine vaccination in Japan, and considerations for accelerating the process
In Japan, a vaccine may not be included in the regular immunization schedule for up to 10 years after approval. This study published in Vaccine, investigated the causes behind the delayed inclusion of vaccines in Japan’s national immunization program. The study concluded that delayed decision-making may be harmful to the public’s health because it takes a long time to obtain epidemiologic information on the frequency of rare, but serious adverse responses and the need for booster doses. Researchers suggest that vaccines need to be included based on the results of clinical trials conducted within a short period, and the need to “strengthen the epidemiological investigation system, including information collection and surveillance of infectious diseases” to assess the burden of disease, adverse reactions, and so on.
https://doi.org/10.1016/j.vaccine.2023.12.058
06
Invasive cervical cancer incidence following bivalent human papillomavirus vaccination: a population-based observational study of age at immunization, dose, and deprivation
This study was published in the Journal of the National Cancer Institute. Analysis of data from the Scottish Cervical Cancer Screening System found that the bivalent HPV vaccine prevented the development of invasive cervical cancer, with no cases of invasive cancer recorded among girls aged 12-13 years old who were vaccinated regardless of the number of doses of vaccine; in older age groups, 3 doses of vaccine were required to achieve statistically significant effectiveness; “Women from more deprived areas benefit more from vaccination than those from less deprived areas.”
https://doi.org/10.1093/jnci/djad263
07
Rational design of a ‘two-in-one’ immunogen DAM drives potent immune response against Mpox virus
Gao Fu’s team at the Institute of Microbiology Chinese Academy of Sciences (IMS) published a research paper in Nature Immunology, in which they have innovatively designed a “two-in-one” recombinant protein vaccine against monkeypox virus (DAM) through a multi-epitope chimeric strategy guided by the antigenic structure, achieving comprehensive protection against two infectious virus particles by a single immunogen——DAM. DAM provides a safer and scalable alternative vaccine for the prevention and control of monkeypox virus, with a neutralization capacity “28 times higher than those induced by live VACV vaccine.”
https://doi.org/10.1038/s41590-023-01715-7
08
Arcturus and PasspPort Tech collaborate to develop skin patch drug delivery system for mRNA vaccines
PassPort Technologies (PPTI) announced a collaborative research effort with Arcturus Therapeutics (ARCT) to develop, evaluate, and commercialize innovative formulations and dermal delivery systems for mRNA vaccine and therapy delivery. The collaboration combines ARCT’s strengths in mRNA design and proprietary LUNAR® platform technology with PPTI’s breakthrough PassPort® transdermal delivery platform technology and experience in transdermal biologics and oligonucleotide delivery to develop mRNA drug candidates that can be dermally administered.
https://mp.weixin.qq.com/s/TJbrxGBxWre7FJ_5TLUC_Q
Content Editor: Linjing(Grace) Zhang
Page Editor: Ziqi Liu
